General Information of Drug Combination (ID: DC55CN2)

Drug Combination Name
Dianicline SR141716A
Indication
Disease Entry Status REF
Tobacco dependence Discontinued [1]
Component Drugs Dianicline   DMX2SHT SR141716A   DMCO5JZ
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Dianicline
Disease Entry ICD 11 Status REF
Tobacco dependence 6C4A.2 Discontinued in Phase 3 [2]
Dianicline Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Neuronal acetylcholine receptor alpha-4/beta-2 (CHRNA4/B2) TTL1ATN ACHA4_HUMAN; ACHB2_HUMAN Modulator [4]
------------------------------------------------------------------------------------
Indication(s) of SR141716A
Disease Entry ICD 11 Status REF
Obesity 5B81 Approved [3]
SR141716A Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Cannabinoid receptor 1 (CB1) TT6OEDT CNR1_HUMAN Antagonist [6]
------------------------------------------------------------------------------------
SR141716A Interacts with 11 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Serine/threonine-protein kinase Chk1 (CHEK1) OTTTI622 CHK1_HUMAN Decreases Phosphorylation [7]
Poly polymerase 1 (PARP1) OT310QSG PARP1_HUMAN Decreases Expression [7]
G2/mitotic-specific cyclin-B1 (CCNB1) OT19S7E5 CCNB1_HUMAN Increases Expression [7]
Alanine aminotransferase 1 (GPT) OTOXOA0Q ALAT1_HUMAN Decreases Expression [8]
G1/S-specific cyclin-D1 (CCND1) OT8HPTKJ CCND1_HUMAN Decreases Expression [9]
Mitogen-activated protein kinase 3 (MAPK3) OTCYKGKO MK03_HUMAN Affects Localization [9]
Mitogen-activated protein kinase 1 (MAPK1) OTH85PI5 MK01_HUMAN Affects Localization [9]
Hepatocyte nuclear factor 4-alpha (HNF4A) OTY1TOAB HNF4A_HUMAN Decreases Activity [10]
Cyclin-dependent kinase inhibitor 1B (CDKN1B) OTNY5LLZ CDN1B_HUMAN Increases Expression [9]
Small ribosomal subunit protein eS6 (RPS6) OTT4D1LN RS6_HUMAN Decreases Phosphorylation [11]
Aurora kinase B (AURKB) OTIY4VHU AURKB_HUMAN Decreases Expression [7]
------------------------------------------------------------------------------------
⏷ Show the Full List of 11 DOT(s)

References

1 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800027143)
2 Emerging drugs for the treatment of tobacco dependence. Expert Opin Emerg Drugs. 2009 Mar;14(1):23-32.
3 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
4 Dianicline, a novel 42 nicotinic acetylcholine receptor partial agonist, for smoking cessation: a randomized placebo-controlled clinical trial.Nicotine Tob Res.2011 Jan;13(1):1-6.
5 Gemcitabine/cannabinoid combination triggers autophagy in pancreatic cancer cells through a ROS-mediated mechanism. Cell Death Dis. 2011 Apr 28;2(4):e152. doi: 10.1038/cddis.2011.36.
6 Anti-obesity drugs. Expert Opin Pharmacother. 2008 Jun;9(8):1339-50.
7 Rimonabant inhibits human colon cancer cell growth and reduces the formation of precancerous lesions in the mouse colon. Int J Cancer. 2009 Sep 1;125(5):996-1003. doi: 10.1002/ijc.24483.
8 Endocannabinoid receptor blockade reduces alanine aminotransferase in polycystic ovary syndrome independent of weight loss. BMC Endocr Disord. 2017 Jul 14;17(1):41. doi: 10.1186/s12902-017-0194-2.
9 The cannabinoid CB1 receptor antagonist rimonabant (SR141716) inhibits human breast cancer cell proliferation through a lipid raft-mediated mechanism. Mol Pharmacol. 2006 Oct;70(4):1298-306. doi: 10.1124/mol.106.025601. Epub 2006 Jul 5.
10 Rimonabant suppresses RNA transcription of hepatitis B virus by inhibiting hepatocyte nuclear factor 4. Microbiol Immunol. 2020 May;64(5):345-355. doi: 10.1111/1348-0421.12777. Epub 2020 Feb 25.
11 Contribution of Altered Endocannabinoid System to Overactive mTORC1 Signaling in Focal Cortical Dysplasia. Front Pharmacol. 2019 Jan 9;9:1508. doi: 10.3389/fphar.2018.01508. eCollection 2018.